Drug Research
Aurisco to Build Oligonucleotides Manufacturing Facility in China
Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production.
The Oligo FlexFactory platform is the first of the...
Drug Research
Sartorius, RoosterBio Partner to Advance the Manufacture of Exosomes
Sartorius has extended a strategic collaboration agreement with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. The companies will provide solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based...
Drug Research
GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation
Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation ("Alcami"), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison...
Drug Research
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
Duality Biologics, a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced a license agreement with Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough...
News
Agilent Technologies Inc. Acquires Avida Biomed
Agilent Technologies Inc. has acquired Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.
The acquisition complements Agilent’s SureSelect portfolio and further augments...
Drug Research
Capsida Biotherapeutics, Prevail Therapeutics Enter Strategic R&D Alliance
Capsida Biotherapeutics Inc. has entered a multi-year strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Co., to develop genetic medicines for serious diseases. Prevail will leverage Capsida's novel adeno-associated virus (AAV) engineering platform to...
Drug Research
Australia Implements New Measure To Lower Cost of Medicines
Millions of Australians will pay up to 29% less for their Pharmaceutical Benefits Scheme (PBS) prescriptions because the maximum PBS co-payment is going down from $42.50 to $30. The co-payment for general scripts has decreased for the first time...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.